Following TOPACIO update at SGO showing additive benefit of PARP and checkpoint inhibition in platinum resistant/refractory ovarian cancer, Wedbush analyst David Nierengarten says Tesaro's announced results are "impressive" considering the advanced population and typically poor response rates observed with chemo re-treatment in setting. Further, the analyst believes the results reflect continued success in the company's strategy to expand addressable Zejula opportunity in ovarian cancer. He reiterates an Outperform rating and $76 price target on the shares.